Live Analyst Rating Changes 1511 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Rudy Li
WLF
Rudy Li
Wolfe Research
Wall Street Analyst
★★★★☆
#268
on 13Foresight · ranked by our own returns
75%
Success Rate
+29.6%
Average Return
12 of 16 calls profitable · +18.9% vs benchmark
📈 Across the calls we could measure, roughly 75% of Rudy Li's ratings turned a profit when each position was held for 1 year — averaging +29.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

34 Buy 3 Hold 0 Sell
Rudy's Stock Coverage 17 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
ACAD
ACADIA Pharmaceuticals
 May 06, 2026 BUY Strong Buy
+66.6% avg upside
42 analysts
$33.00
53.05% Upside
 +0.6%
PRAX
Praxis Precision Medicines
 Apr 06, 2026 BUY Strong Buy
+96.4% avg upside
24 analysts
$500.00
77.11% Upside
 -14.1%
NBIX
Neurocrine
 Apr 06, 2026 BUY Strong Buy
+8.0% avg upside
37 analysts
$160.00
1.92% Upside
 +20.6%
CNTA
Centessa Pharmaceuticals
 Mar 31, 2026 HOLD Buy
-14.1% avg upside
19 analysts
 — +0.3%
AXSM
Axsome Therapeutics
 Feb 23, 2026 BUY Strong Buy
-10.5% avg upside
28 analysts
$230.00
7.77% Downside
 +44.1%
ALKS
Alkermes
 Feb 23, 2026 BUY Strong Buy
-16.4% avg upside
34 analysts
$45.00
1.69% Upside
 +40.9%
QURE
uniQure
 Feb 23, 2026 HOLD Strong Buy
+2.0% avg upside
29 analysts
 — +1.0%
XENE
Xenon
 Feb 23, 2026 BUY Strong Buy
+18.6% avg upside
28 analysts
$60.00
12.72% Upside
 +22.7%
DFTX
Definium Therapeutics
 Feb 23, 2026 BUY Strong Buy
+46.3% avg upside
20 analysts
$25.00
3.17% Upside
 +44.1%
GB:0NZT
UCB SA
 Feb 23, 2026 BUY Buy
-13.5% avg upside
19 analysts
$340.00
36.47% Upside
 ·
DNLI
Denali Therapeutics
 Feb 23, 2026 HOLD Strong Buy
+58.8% avg upside
24 analysts
 — +5.1%
STOK
Stoke Therapeutics
 Feb 23, 2026 BUY Strong Buy
+28.2% avg upside
18 analysts
$40.00
31.75% Upside
 -17.2%
IMUX
Immunic
 Dec 31, 2025 BUY Strong Buy
+166.9% avg upside
21 analysts
$30.00
113.56% Upside
 +159.5%
PRTA
Prothena
 Dec 31, 2025 BUY Buy
+171.8% avg upside
14 analysts
$18.00
102.47% Upside
 -11.1%
ANRO
Alto Neuroscience, Inc.
 Oct 20, 2025 BUY Strong Buy
+37.7% avg upside
13 analysts
$15.00
32.80% Downside
 +92.5%
RVPH
Reviva Pharmaceuticals Holdings
 Sep 29, 2025 BUY Strong Buy
+7391.6% avg upside
9 analysts
$40.00
6566.66% Upside
 -88.4%
DRUG
Bright Minds Biosciences
 May 21, 2025 BUY Strong Buy
+124.9% avg upside
10 analysts
$80.00
34.11% Upside
 +173.6%
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Rudy Li — Frequently Asked Questions
How accurate are Rudy Li's stock ratings?
Based on the calls 13Foresight could measure, about 75% of Rudy's ratings were profitable over a one-year hold, with an average return of +29.6% per rating, or +18.9% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Rudy ranked on 13Foresight?
Rudy Li is currently ranked #268 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Rudy cover?
Rudy most recently has ratings on ACAD, PRAX, NBIX, CNTA, AXSM, ALKS, QURE, XENE, DFTX, GB:0NZT, DNLI, STOK and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.